These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2877854)

  • 1. Variables affecting efficacy and toxicity of sulphasalazine in rheumatoid arthritis. A review.
    Pullar T; Capell HA
    Drugs; 1986; 32 Suppl 1():54-7. PubMed ID: 2877854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sulphasalazine for rheumatoid arthritis. Studies on dose, acetylator phenotype and efficacy.
    Amos RS; Bax DE; Greaves MS
    Drugs; 1986; 32 Suppl 1():58. PubMed ID: 2877855
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of acetylator phenotype on efficacy and toxicity of sulphasalazine in rheumatoid arthritis.
    Pullar T; Hunter JA; Capell HA
    Ann Rheum Dis; 1985 Dec; 44(12):831-7. PubMed ID: 2867746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphasalazine for rheumatoid arthritis: relationship between dose, acetylator phenotype and response to treatment.
    Bax DE; Greaves MS; Amos RS
    Br J Rheumatol; 1986 Aug; 25(3):282-4. PubMed ID: 2873862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
    Pullar T; Hunter JA; Capell HA
    Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term outcome of treatment with sulphasalazine in rheumatoid arthritis.
    Situnayake RD; McConkey B
    Drugs; 1986; 32 Suppl 1():71-2. PubMed ID: 2877857
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis.
    Kitas GD; Farr M; Waterhouse L; Bacon PA
    Scand J Rheumatol; 1992; 21(5):220-5. PubMed ID: 1359635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulphasalazine in the long term management of rheumatoid arthritis.
    Bax DE; Amos RS
    Drugs; 1986; 32 Suppl 1():73-6. PubMed ID: 2877858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
    Taggart AJ; McDermott B; Delargy M; Elborn S; Forbes J; Roberts SD; Ahnfelt NO
    Scand J Rheumatol Suppl; 1987; 64():29-36. PubMed ID: 2893450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphasalazine induced three-week syndrome.
    Suresh R; Gupta S; Sathananthan R
    J Clin Rheumatol; 2009 Sep; 15(6):311-2. PubMed ID: 19734741
    [No Abstract]   [Full Text] [Related]  

  • 12. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate.
    Pullar T; Hunter JA; Capell HA
    Br Med J (Clin Res Ed); 1983 Oct; 287(6399):1102-4. PubMed ID: 6138117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results.
    Georgescu C
    Rom J Intern Med; 1992; 30(2):127-32. PubMed ID: 1353901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Symposium on enteric-coated sulphasalazine in rheumatoid arthritis. Proceedings of a symposium. London, December 6, 1985.
    Drugs; 1986; 32 Suppl 1():1-80. PubMed ID: 2877848
    [No Abstract]   [Full Text] [Related]  

  • 16. Sulfasalazine-induced aseptic meningitis with positive rechallenge: a case report and review of the literature.
    Salouage I; El Aïdli S; Cherif F; Kastalli S; Zaiem A; Daghfous R
    Therapie; 2013; 68(6):423-6. PubMed ID: 24356191
    [No Abstract]   [Full Text] [Related]  

  • 17. Does sulphasalazine cause folate deficiency in rheumatoid arthritis?
    Grindulis KA; McConkey B
    Scand J Rheumatol; 1985; 14(3):265-70. PubMed ID: 2864741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effect profile of 200 patients with inflammatory arthritides treated with sulphasalazine.
    Farr M; Scott DG; Bacon PA
    Drugs; 1986; 32 Suppl 1():49-53. PubMed ID: 2877853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulphasalazine: a 'new' antirheumatic drug.
    Pullar T; Capell HA
    Br J Rheumatol; 1984 Feb; 23(1):26-34. PubMed ID: 6141832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.